Molecule
Dermatophagoides farinae is a standardized insect allergenic extract indicated in the diagnosis of patients with a history of allergy to mites or house dust and for the treatment of patients with a history of mite allergy. MedsAcross supplies Dermatophagoides farinae for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Standardized mite extract is indicated for use in the diagnosis of patients with a history of allergy to mites or house dust and for the treatment of patients with a history of mite allergy who have established sensitivity to mites by diagnostic skin testing. The use of mite extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook.
Source: US FDA prescribing information
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The product should be discarded if discoloration or particles are observed. DIAGNOSTIC USE: Percutaneous Tests: The skin test concentration of 10,000 AU/mL in dropper vials is used for scratch or prick-puncture testing. Puncture tests performed with D. farinae extract on 5 persons sensitive to mite showed a mean diameter wheal of 8.8 mm ± 1.8 mm and mean diameter erythema of 39.2 mm ± 5.3 mm. Puncture tests with D. pteronyssinus extract on 10 persons sensitive to mite showed a mean diameter wheal of 7.8 mm ± 4.1 mm and mean erythema of 33.7 mm ± 12.0 mm.
Source: US FDA prescribing information
Injections of mite extract should not be administered in the presence of diseases characterized by a bleeding diathesis. Immunotherapy should not be started in patients until a specific diagnosis of Type I allergy to mite is made by a physician based on skin testing with this product. Other contraindications include: EXTREME SENSITIVITY TO MITE: Determined from previous anaphylaxis following skin testing, immunotherapy, or natural exposure. AUTOIMMUNE DISEASE: Individuals with autoimmune disease maybe at risk, due to the possibility of routine immunizations exacerbating symptoms of the underlying disease.
Source: US FDA prescribing information
This product is intended for use by physicians who are experienced in the administration of allergenic extracts or for use under the guidance of an allergy specialist. The initial dose must be based on skin testing as described in the dosage and administration section of this insert. Concentrated extract must be diluted with sterile diluent prior to first use on a patient for treatment or intradermal testing. All concentrates of allergenic extract are manufactured to assure high potency and therefore have the ability to cause serious local and systemic reactions, including death in sensitive patients. Patients should be informed of this risk and precautions should be discussed prior to initiating immunotherapy.
Source: US FDA prescribing information
Adverse systemic reactions usually occur within minutes and consist primarily of allergic symptoms such as generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema and hypotension. Less commonly, nausea, emesis, abdominal cramps, diarrhea and uterine contractions may occur. Severe reactions may cause shock and loss of consciousness. Fatalities have occurred rarely. Systemic reactions occur with varying frequency in different clinics. To some extent, the reaction rate is related to the type and dose of administered extract and to the degree of sensitivity of the patient. Despite all precautions, occasional reactions are unavoidable. Reports from regulatory authorities in Sweden to the Center for Biologics Evaluation and Research (CBER) indicated that several deaths have been associated with the use of mite extracts.
Source: US FDA prescribing information
STORAGE AND HANDLING Extract should be stored at 2-8°C since higher temperatures may adversely affect stability. Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Dermatophagoides farinae, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dermatophagoides farinae 10000 AU/mL injectionCutaneous, intradermal, subcutaneous Cold chainGeneric name | — | US FDA | Available on request |
| Standardized Mite Dermatophagoides farinae 10000 AU/mL injectionIntradermal, percutaneous, subcutaneous Cold chain | Greer Laboratories | US FDA | Available on request |
| Standardized Mite Dermatophagoides farinae 30000 AU/mL injectionIntradermal, percutaneous, subcutaneous Cold chain | Greer Laboratories | US FDA | Available on request |
| Standardized Mite Dermatophagoides farinae 5000 AU/mL injectionIntradermal, percutaneous, subcutaneous Cold chain | Greer Laboratories | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 4 presentations of Dermatophagoides farinae and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Dermatophagoides farinae, including Standardized Mite Dermatophagoides farinae.
At least one listed presentation of Dermatophagoides farinae must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.